Zacks Investment Research cuts sale of Establishment Labs (NASDAQ: ESTA)

Establishment laboratories (NASDAQ: ESTA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday, reports.

According to Zacks, “Establishment Labs Holdings Inc. is a medical technology company. It focuses on the design, development, manufacture and marketing of a portfolio of silicone gel filled breast implants and body contouring implants. The company’s brand consists of Motiva Implants (R) and the MotivaImagine (R) platform. Its technology portfolio includes Divina 3D Simulation System (R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK. “

Separately, Stephens raised its target price on Establishment Labs from $ 88.00 to $ 90.00 and rated the stock “overweight” in a Wednesday, November 10 research note. One investment analyst rated the stock with a sell rating, another assigned a conservation rating, and four assigned a buy rating to the stock. According to, Establishment Labs currently has an average “Buy” rating and a consensus target price of $ 85.50.

ESTA shares traded down $ 2.35 during trading hours on Friday, reaching $ 61.57. 141,384 shares of the company were traded, for an average volume of 99,917. The company has a rapid ratio of 3.22, a current ratio of 4.10 and a debt ratio of 0.83. The company has a market cap of $ 1.48 billion, a P / E ratio of -45.61 and a beta of 1.13. The company has a 50-day moving average of $ 66.80 and a two-hundred-day moving average of $ 72.18. Establishment Labs has a fifty-two week low of $ 37.26 and a fifty-two week high of $ 88.66.

(A d)

This guide will help you identify and execute an options trading strategy that matches your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Establishment Labs (NASDAQ: ESTA) last announced its results on Tuesday, November 9. The company reported ($ 0.61) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($ 0.34) from ($ 0.27). Establishment Labs recorded a negative return on equity of 46.91% and a negative net margin of 27.54%. The company posted revenue of $ 29.04 million for the quarter, compared to analysts’ estimates of $ 27.50 million. During the same period of the previous year, the company achieved earnings per share ($ 0.18). On average, stock analysts forecast Establishment Labs to post earnings per share of -1.37 for the current fiscal year.

In addition, director Edward J. Schutter acquired 2,467 shares of the company in a transaction dated Tuesday, November 23. The stock was purchased at an average price of $ 62.50 per share, for a total transaction of $ 154,187.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC’s website. In addition, director Edward J. Schutter acquired 2,560 shares of the company in a transaction dated Wednesday, November 17. The stock was purchased at an average price of $ 69.00 per share, for a total value of $ 176,640.00. Disclosure of this purchase can be found here. Company insiders own 13.08% of the company’s shares.

Hedge funds and other institutional investors have recently changed their holdings in the company. Tiedemann Advisors LLC acquired a new equity interest in Establishment Labs during the second quarter valued at approximately $ 232,000. Northern Trust Corp increased its position in Establishment Labs shares by 76.6% in the second quarter. Northern Trust Corp now owns 23,561 shares of the company valued at $ 2,058,000 after acquiring an additional 10,220 shares in the last quarter. State Street Corp acquired a new stake in the shares of Establishment Labs during the second quarter valued at approximately $ 1,380,000. Jump Financial LLC increased its position in the shares of Establishment Labs by 303.3% during the 2nd quarter. Jump Financial LLC now owns 13,514 shares of the company valued at $ 1,180,000 after acquiring an additional 10,163 shares in the last quarter. Finally, BNP Paribas Arbitrage SA acquired a new stake in the shares of Etablissement Labs during the second quarter for an amount of approximately $ 29,000. 60.23% of the shares are currently held by institutional investors and hedge funds.

About establishment laboratories

Establishment Labs Holdings, Inc is a technology company engaged in the design, development, manufacture and marketing of silicone breast implants. It operates through the following geographic segments: Europe, Latin America, Asia-Pacific and Middle East, and others. The company’s products include Motiva Implants, Motiva Flora Tissue Expander, Divina and Puregraft.

See also: Municipal bonds

Get a free copy of Zacks’ Establishment Laboratory Research Report (ESTA)

For more information on Zacks Investment Research’s research offerings, visit

Analyst Recommendations for Institutional Laboratories (NASDAQ: ESTA)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Establishment Labs now?

Before you consider Establishment Labs, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Establishment Labs was not on the list.

Although Establishment Labs currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

About Meredith Campagna

Check Also

Oil prices and financial markets brace for recession

US economic data remains strong, but a range of financial indicators point to a sharp …